Abstract:In oral delivery of biomacromolecules, ligand-modified nanoparticles (NPs) have emerged as a promising tool to improve the epithelial uptake of the loaded protein/peptide. Unfortunately, the stability and the transport mechanisms of the biotherapeutics during the intracellular transportation still remained unclear, leading to the poor transepithelial efficiency. Additionally, developing novel approaches to simultaneously monitor the payload bioactivity during the transport processes is veritably benefit for keeping their bioactivity. In the present study, EGP peptide (KRKKKGKGLGKKRDPCLRKYK), a ligand with high affinity to heparan sulfate proteoglycans (HSPGs), was found remarkably increasing the cellular uptake (4.5-fold) and also surprisingly achieving high transcytosis efficiency (4.2-fold) of poly(lactide- co-glycolide) NPs on Caco-2 cell monolayer. Compared with unmodified NPs (C NPs), EGP modified NPs (EGP NPs) exhibited more desirable colloidal stability within epithelia. In the subsequent study, the bioactivity of encapsulated insulin during the cellular transportation was innovatively monitored by a glucose consumption assay. Inspiringly, EGP NPs could mostly retain the bioactivity of loaded insulin whereas insulin from INS-C NPs was significantly degraded. Then the detailed mechanism study revealed that the binding of EGP to HSPGs played a vital role on NP transportation. Unlike C NPs being delivered in the endo/lysosomal pathway, EGP NPs were involved in caveolae-mediated transport, which contributes to the efficient avoidance of the lysosomal entrapment and sequentially facilitates the direct apical-to-basolateral transcytosis. The enhanced absorption of EGP NPs was confirmed in in situ intestinal loop models. Most importantly, oral administrated INS-EGP NPs generated a strong hypoglycemic response on diabetic rats with 10.2-fold and 2.6-fold increase in bioavailability compared with free insulin and INS-C NPs, respectively. The work provided an innovative strategy to monitor the payload bioactivity during the transport processes and proposed a novel aspect to increase oral bioavailability of biomacromolecules via improving payload stability and regulating the transcytosis pathway of nanocarriers.

Lipid Nanovehicles with Adjustable Surface Properties for Overcoming Multiple Barriers Simultaneously in Oral Administration.

Functional lipid polymeric nanoparticles for oral drug delivery: Rapid mucus penetration and improved cell entry and cellular transport

A Strategy for Developing Effective Orally-Delivered Nanoparticles Through Modulation of the Surface "hydrophilicity/hydrophobicity Balance".

Effects of surface hydrophilic properties of PEG-based mucus-penetrating nanostructured lipid carriers on oral drug delivery

Sub‐50 Nm Nanoparticles with Biomimetic Surfaces to Sequentially Overcome the Mucosal Diffusion Barrier and the Epithelial Absorption Barrier

Bilayer-functionalized mesoporous silica nanoparticles for overcoming multiple barriers of mucus clearance, intestinal epithelium and P-glycoprotein efflux

In Situ Rearranged Multifunctional Lipid Nanoparticles Via Synergistic Potentiation for Oral Insulin Delivery.

Oral In-Situ Nanoplatform with Balanced Hydrophobic-Hydrophilic Property for Transport Across Gastrointestinal Mucosa

Modulating Intestinal Mucus Barrier for Nanoparticles Penetration by Surfactants

Efficient Mucus Permeation and Tight Junction Opening by Dissociable "Mucus-Inert" Agent Coated Trimethyl Chitosan Nanoparticles for Oral Insulin Delivery.

Enhanced Oral Delivery of Protein Drugs Using Zwitterion-Functionalized Nanoparticles to Overcome Both the Diffusion and Absorption Barriers

Overcoming Multiple Gastrointestinal Barriers by Bilayer Modified Hollow Mesoporous Silica Nanocarriers.

Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery

Enhanced Oral Absorption and Liver Distribution of Polymeric Nanoparticles Through Traveling the Enterohepatic Circulation Pathways of Bile Acid

Systematic Evaluation of the Toxicity and Biodistribution of Virus Mimicking Mucus-Penetrating DLPC-NPs As Oral Drug Delivery System.

Hydrophilic and Electroneutral Nanoparticles to Overcome Mucus Trapping and Enhance Oral Delivery of Insulin

Enhanced Transport of Shape and Rigidity-Tuned Α-Lactalbumin Nanotubes Across Intestinal Mucus and Cellular Barriers

Multifunctional Nanoparticles Enable Efficient Oral Delivery of Biomacromolecules Via Improving Payload Stability and Regulating the Transcytosis Pathway.

Core-shell Stability of Nanoparticles Plays an Important Role for Overcoming the Intestinal Mucus and Epithelium Barrier.

Improved Transport and Absorption Through Gastrointestinal Tract by PEGylated Solid Lipid Nanoparticles

Engineering Nanomaterials to Overcome the Mucosal Barrier by Modulating Surface Properties